Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial"

被引：3

作者：

Gronda, Edoardo ^{[1
]}

Colivicchi, Furio ^{[2
]}

Zuccala, Giuseppe ^{[3
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Nefrol Dialisi & Trapianto Renale Adulto, Milan, Italy

[2] Azienda Complesso Osped San Filippo Neri, Rome, Italy

[3] Fdn Policlin Univ Agostino Gemelli IRCSS, Cardiol Clin & Riabilitat, Rome, Italy

来源：

CIRCULATION | 2022年 / 145卷 / 16期

关键词：

D O I：

10.1161/CIRCULATIONAHA.121.057530

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E839 / E840

页数：2

共 50 条

[21] A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'
Pabel, Steffen
Hamdani, Nazha
Sossalla, Samuel
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (05) : 841 - 841
[22] Response by Pfeffer et al to Letter Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective"
Pfeffer, Marc A.
Shah, Amil M.
Borlaug, Barry A.
[J]. CIRCULATION RESEARCH, 2019, 125 (04) : E26 - E26
[23] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
Butler, Javed
Filippatos, Gerasimos
[J]. FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
[24] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
de Abreu, Tiago Tribolet
[J]. HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
[25] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
Tiago Tribolet de Abreu
[J]. Heart Failure Reviews, 2022, 27 : 2077 - 2082
[26] Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
Filippatos, Gerasimos
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 134 - 135
[27] Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'
Kokhan, Elizaveta
Kiyakbaev, Gayrat
Medovchshikov, Vadim
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (07) : 1323 - 1324
[28] Letter by Nunez et al Regarding Article, "Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction"
Nunez, Eduardo
Sanchis, Juan
Nunez, Julio
[J]. CIRCULATION-HEART FAILURE, 2013, 6 (02) : E25 - E25
[29] Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Boehm, Michael
Butler, Javed
Mahfoud, Felix
Filippatos, Gerasimos
Ferreira, Joao Pedro
Pocock, Stuart J.
Slawik, Jonathan
Brueckmann, Martina
Linetzky, Bruno
Schueler, Elke
Wanner, Christoph
Zannad, Faiez
Packer, Milton
Anker, Stefan D.
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1883 - 1891
[30] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
不详
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21):

← 1 2 3 4 5 →